EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on January 15, 2025, allow the purchase of up to 30,300 shares of common stock at an exercise price of $7.69 per share, matching the closing price on the grant date.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha concesso opzioni su azioni non statutarie a quattro nuovi dipendenti come premi di indennizzo al di fuori del suo Piano di Incentivi a Lungo Termine 2023. I conferimenti, approvati dal Comitato Compensi il 15 gennaio 2025, consentono l'acquisto di fino a 30.300 azioni di azioni ordinarie a un prezzo di esercizio di $7,69 per azione, corrispondente al prezzo di chiusura nella data del conferimento.
Le opzioni hanno un termine di dieci anni e seguono un piano di maturazione di quattro anni: il 25% matura il primo anniversario, con le azioni rimanenti che matura in rate mensili uguali nei tre anni successivi. La maturazione è subordinata al mantenimento dell'impiego con EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha otorgado opciones de acciones no estatutarias a cuatro nuevos empleados como premios de incentivo fuera de su Plan de Incentivos a Largo Plazo 2023. Las concesiones, aprobadas por el Comité de Compensación el 15 de enero de 2025, permiten la compra de hasta 30,300 acciones ordinarias a un precio de ejercicio de $7.69 por acción, coincidiendo con el precio de cierre en la fecha de concesión.
Las opciones tienen un plazo de diez años y siguen un cronograma de adquisición de cuatro años: el 25% se adquiere en el primer aniversario, y las acciones restantes se adquieren en cuotas mensuales iguales durante los siguientes tres años. La adquisición está sujeta a la continuación del empleo con EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 2023년 장기 인센티브 계획 외부에서 유인 상으로 네 명의 새로운 직원에게 비상 statutory 주식 옵션을 부여했습니다. 이 보너스는 2025년 1월 15일 보상위원회에서 승인되었으며, 30,300주의 보통주를 주당 $7.69의 행사 가격으로 구매할 수 있습니다. 이는 부여일의 종가와 일치합니다.
이 옵션은 10년의 기간을 가지며 4년의 베스팅 일정에 따릅니다: 첫 번째 기념일에 25%가 베스팅되고, 나머지 주식은 이후 3년 동안 매월 동일한 분할로 베스팅됩니다. 베스팅은 EyePoint와의 지속적인 고용에 따라 달라집니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT) a accordé des options d'achat d'actions non statutaires à quatre nouveaux employés en tant que récompenses de motivation en dehors de son Plan d'Incitation à Long Terme 2023. Les attributions, approuvées par le Comité de Rémunération le 15 janvier 2025, permettent l'achat de jusqu'à 30 300 actions ordinaires à un prix d'exercice de 7,69 $ par action, correspondant au prix de clôture à la date de l'attribution.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition de quatre ans : 25 % de l'acquisition a lieu lors du premier anniversaire, les actions restantes s'acquérant par mensualités égales au cours des trois années suivantes. L'acquisition dépend du maintien de l'emploi avec EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT) hat vier neuen Mitarbeitern außerhalb des 2023 Long-Term Incentive Plans nicht-statutäre Aktienoptionen als Anreizpreise gewährt. Die Vergaben, die am 15. Januar 2025 vom Vergütungsausschuss genehmigt wurden, erlauben den Kauf von bis zu 30.300 Aktien zu einem Ausübungspreis von 7,69 USD pro Aktie, was dem Schlusskurs am Vergabedatum entspricht.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Zeitplan: 25% vesten am ersten Jahrestag, die verbleibenden Aktien vesten in gleichen monatlichen Raten über die folgenden drei Jahre. Das Vesting ist von der Fortsetzung der Beschäftigung bei EyePoint abhängig.
- None.
- None.
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint Pharmaceuticals:
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
How many shares were included in EYPT's January 2025 employee stock option grants?
What is the exercise price for EYPT's January 2025 employee stock options?
What is the vesting schedule for EYPT's January 2025 employee stock options?
How long is the term of EYPT's January 2025 employee stock options?
